LONDON,?June 30, 2020?/PRNewswire/ -- TRI will conduct an open-label randomized controlled trial of community-based early thromboprophylaxis named ETHIC (Early Thromboprophylaxis in COVID-19). ?Eligible patients will have newly-diagnosed Covid-19 and also have been identified with an increased risk of complications of infection due to age and comorbidities. The study was designed in response to recent evidence suggesting that severe COVID-19 infections are associated with increased frequency of thrombosis. Symptomatic patients with COVID-19 receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care. The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days. Symptomatic COVID-19 patients receiving the LMWH (via enoxaparin) will be compared with patients receiving the standard of care. . The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days. The study will be funded by an investigator-initiated study grant provided by Sanofi. TRI Director?Ajay Kakkar?said: "Our understanding of the role of thrombosis and anticoagulation in COVID-19 is rapidly evolving. We greatly appreciate the opportunity to engage our global network of researchers in the evaluation of anticoagulation in COVID-19 in the community setting for the first time. We are immensely grateful to the colleagues and patients who will participate in this important study." The Thrombosis Research Institute is a leader in innovative solutions for the detection and treatment of thrombosis. Sanofi is a global biopharmaceutical company focused on improving human health. Logo -?https://mma.prnewswire.com/media/1195593/ETHIC_Logo.jpg SOURCE Thrombosis Research Institute (TRI)